In addition to the day-to-day team, we have assembled the world’s leading experts on transdermal drug delivery, smoking cessation and pharmaceutical commercialization to inform the company’s activities.
With decades of combined experience in research and product development, behavioral science, FDA approval experience, and bringing life-saving products to market, our team possesses a wide-array of knowledge and skills that will help define the next generation of medication delivery.
Alan Levy, Ph.D.
Chairman and Chief Executive Officer
Chief Financial Officer
Patricia Oto, R.Ph.
Senior Vice President of Regulatory Affairs and Quality Assurance
Patrick H. Ruane, Ph.D.
Senior Vice President of Research and Development
Vice President of Engineering
James W. Young
Venture Partner, 5AM Ventures
Chairman and Chief Executive Officer, Chrono Therapeutics
Former Chief Executive Officer, Labrys Biologics, Inc. and KAI Pharmaceuticals, Inc.
General Partner, Canaan Partners
Co-founder and Managing Partner, Fountain Healthcare
Director, Kaiser Permanente Ventures
Chief Executive Officer, Mazlo and Former Chief Executive Officer, Free & Clear, Inc.
Gary E. Swan, Ph.D.
Consulting Professor Stanford Prevention Research Center at Stanford University School of Medicine
Jonathan Bricker, Ph.D.
Faculty Member at the University of Washington and the Fred Hutchinson Cancer Research Center
Richard D. Hurt, M.D.
Founder and Former Director of the Nicotine Dependence Center at the Mayo Clinic
Neal Benowitz, M.D.
UCSF School of Medicine
Karl Fagerström, Ph.D.
Fagerström Consulting AB